39762 Investors following Ranbaxy Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Ranbaxy Lab sees CY07 margins at 16%
Ranbaxy Lab has announced its first quarter results. The company's net profit was up at Rs 128 crore (Rs 1.28 billion) versus Rs 71.4 crore (Rs 714 million), YoY.
Ranbaxy Laboratories has announced its first quarter results. The company's net profit was up at Rs 128 crore (Rs 1.28 billion) versus Rs 71.4 crore (Rs 714 million), YoY.
Ranbaxy Q1 net sales stood at Rs 1,564.4 crore (Rs 15.64 billion) versus Rs 1,263.1 crore (Rs 12.63 billion).
Forex gain for first quarter was at Rs 55.9 crore (Rs 559 million) as against Rs 5.9 crore (Rs 59 million).
Other Points:
-Integration of Terapia into the Ranbaxy fold having been completed -The India region sales grew by 24%.. During the quarter, the India business launched 18 new products -Sales in North America grew 3% at USD 91 Mn, -Emergimg markets business contributed to 54% of revenues and grew at 53% in the quarter -78% growth recorded in Europe for the quarter -Romania recorded slaes growth of 50% of $37mn -Asia Pacific & CIS region recorded a growth of 32% combined sales of USD 115 Mn for the quarter,
-Guidance 20% sales growth for CY07 -20% growth guidance does not include the exclusivity wins CY07 Margins Seen At 16%
-88 Products Pending for US FDA Approval with market size of $56bn -20 First-to-file ANDAs, With Market Size Of $26 Bn -To Launch 1 product with 180-day exclusivity every year -Have launched 4-5 new products in Q1 in US
-Strengthening Biz in SAfrica to become 5th Largest Generic co through Be-tabs acquisition which will close in May this year -Acquisition focus mainly in emerging markets in Branded Generics space
Ranbaxy Laboratories
